Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 5/2014

01-05-2014

Morbidity of Chemotherapy Administration and Satisfaction in Breast Cancer Patients: A Comparative Study of Totally Implantable Venous Access Device (TIVAD) Versus Peripheral Venous Access Usage

Authors: Kul Ranjan Singh, Gaurav Agarwal, Gitika Nanda, Gyan Chand, Anjali Mishra, Amit Agarwal, Ashok K. Verma, Saroj K. Mishra, Puneet Goyal

Published in: World Journal of Surgery | Issue 5/2014

Login to get access

Abstract

Background

This prospective, non-randomized, comparative study evaluated morbidity of chemotherapy administration via a totally implantable venous access device (TIVAD) versus peripheral intravenous access (PIVA), and satisfaction in breast cancer patients in a limited-resource setting.

Methods

Consecutive patients receiving chemotherapy via TIVAD (n = 114) or PIVA (n = 159) were studied. Venous access-related events were recorded. Morbidity and satisfaction with TIVAD or PIVA as perceived by the patients were assessed using a specifically designed questionnaire, which patients filled after 1st cycle of, and after completion of all chemotherapy.

Results

Patients in the two groups were of comparable age, body mass index, and disease stage. Acceptance of TIVAD was higher in literate patients. TIVAD did not interfere with sleep or activities in 90 % of patients. The majority (81.2 %) were satisfied with the cosmetic outcome, 91.5 % would have TIVAD re-inserted if the need arose, and 89.6 % would recommend it to others. Non-fatal complications occurred in 16 patients, and TIVAD had to be removed prematurely in five patients. In the PIVA group, 40 % needed multiple needle pricks and 55.8 % developed thrombophlebitis or staining of arms. Drug extravasation and ulceration were suffered by 8.3 and 4.2 %, respectively. However, 78.3 % of patients reported no interference with daily activities and only 26 % would prefer a TIVAD. Those receiving more than six chemotherapy cycles were dissatisfied to a greater extent with PIVA (p < 0.05).

Conclusions

Breast cancer chemotherapy via TIVAD is safe and convenient and results in high satisfaction levels, although it involves additional expenditure. Chemotherapy via PIVA is acceptable, albeit with lower satisfaction, more so in those receiving more than six chemotherapy cycles.
Literature
1.
Niederhuber JE, Ensminger W, Gyves JW et al (1982) Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 92(4):706–712PubMed
2.
Zaghal A, Khalife M, Mukherji D et al (2012) Update on totally implantable venous access devices. Surg Oncol 21(3):207–215PubMedCrossRef
3.
Jan HC, Chou SJ, Chen TH et al (2012) Management and prevention of complications of subcutaneous intravenous infusion port. Surg Oncol 21(1):7–13PubMedCrossRef
4.
Di Carlo I, Pulvirenti E, Mannino M et al (2010) Increased use of percutaneous technique for totally implantable venous access devices. Is it real progress? A 27-year comprehensive review on early complications. Ann Surg Oncol 7(6):1649–1656CrossRef
5.
Kim JT, Oh TY, Chang WH et al (2012) Clinical review and analysis of complications of totally implantable venous access devices for chemotherapy. Med Oncol 29(2):1361–1364PubMedCrossRef
6.
Bow EJ, Kilpatrick MG, Clinch JJ (1999) Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: a randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life. J Clin Oncol 17(4):1267PubMed
7.
Kreis H, Loehberg CR, Lux MP et al (2007) Patients’ attitudes to totally implantable venous access port systems for gynecological or breast malignancies. Eur J Surg Oncol 33(1):39–43PubMedCrossRef
8.
Johansson E, Engervall P, Björvell H et al (2009) Patients’ perceptions of having a central venous catheter or a totally implantable subcutaneous port system: results from a randomised study in acute leukaemia. Support Care Cancer 17(2):137–143PubMedCrossRef
9.
Ignatov A, Hoffman O, Smith B et al (2009) An 11-year retrospective study of totally implanted central venous access ports: complications and patient satisfaction. Eur J Surg Oncol 35(3):241–246PubMedCrossRef
10.
Agarwal G, Pradeep PV, Aggarwal V et al (2007) Spectrum of breast cancer in Asian women. World J Surg 31:1031–1040PubMedCrossRef
11.
Agarwal G, Aggarwal V, Lal P et al (2008) Feasibility study of safe breast conservation in large and locally-advanced breast cancers with use of radio-opaque markers to mark pre-neo adjuvant chemotherapy tumor margins. World J Surg 32(12):2562–2569PubMedCrossRef
12.
Sticca RP, Dewing BD, Harris J et al (2009) Outcomes of surgical and radiologic placed implantable central venous access ports. Am J Surg 198(6):829–833PubMedCrossRef
13.
Borst CG, De Kruif AT, Van Dam FS (1992) Totally implantable venous access ports-the patients’ point of view: a quality control study. Cancer Nurs 15(5):378PubMedCrossRef
14.
Wincent A, Lidén Y, Arnér S (2003) Pain questionnaires in the analysis of long lasting (chronic) pain conditions. Eur J Pain 7(4):311–321PubMedCrossRef
15.
Narducci F, Jean-Laurent M, Baulanger L et al (2011) Totally implantable venous access port systems and risk factors for complications: a one year prospective study in a cancer centre. Eur J Surg Oncol 37:913–918PubMedCrossRef
16.
Goossens GA, Vrebos M, Stas M et al (2005) Central vascular access devices in oncology and hematology considered from a different point of view: how do patients experience their vascular access ports? J Infus Nurs 28(1):61–67PubMedCrossRef
Metadata
Title
Morbidity of Chemotherapy Administration and Satisfaction in Breast Cancer Patients: A Comparative Study of Totally Implantable Venous Access Device (TIVAD) Versus Peripheral Venous Access Usage
Authors
Kul Ranjan Singh
Gaurav Agarwal
Gitika Nanda
Gyan Chand
Anjali Mishra
Amit Agarwal
Ashok K. Verma
Saroj K. Mishra
Puneet Goyal
Publication date
01-05-2014
Publisher
Springer US
Published in
World Journal of Surgery / Issue 5/2014
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-013-2378-x

Other articles of this Issue 5/2014

World Journal of Surgery 5/2014 Go to the issue

OriginalPaper

Wide Resection of Inguinal Nerves versus Simple Section to Prevent Postoperative Pain after Prosthetic Inguinal Hernioplasty: Our Experience

OriginalPaper

In Hepatocellular Carcinomas, any Proportion of Poorly Differentiated Components is Associated with Poor Prognosis After Hepatectomy

OriginalPaper

Health-Related Quality of Life After Robot-Assisted Distal Gastrectomy in Early Gastric Cancer

OriginalPaper

Neoadjuvant Therapy and Vascular Resection During Pancreaticoduodenectomy: Shifting the Survival Curve for Patients with Locally Advanced Pancreatic Cancer

OriginalPaper

A Simple Risk Score to Predict the Presence of Non-Sentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node

OriginalPaper

Clinical Analysis of Anatomical Resection for the Treatment of Hepatocellular Carcinoma Based on the Stratification of Liver Function